Atypical chronic myeloid leukemia: A rare entity with management challenges

Prajwal Dhakal, Krishna Gundabolu, Catalina Amador, Supratik Rayamajhi, Vijaya R Bhatt

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The aim of our study was to review the clinicopathologic features and management of atypical chronic myeloid leukemia (aCML). Relevant manuscripts published in English were searched using PubMed. aCML is diagnosed as per WHO 2016 classification in the presence of leukocytosis ≥13 × 109/l with circulating neutrophil precursors ≥10%, monocytes less than 10%, minimal basophils, hypercellular bone marrow with granulocytic proliferation and dysplasia, bone marrow blast less than 20% and absence of BCR/ABL fusion gene. Common cytogenetic features and mutations include trisomy 8, and mutations in SETBP1 and ETNK1. Median survival is 1-2 years. Hematopoietic stem cell transplant may be the only curative option. Ruxolitinib and dasatinib are emerging therapeutic options. Thus, aCML is a rare entity with poor survival. Novel therapies are needed.

Original languageEnglish (US)
Pages (from-to)177-185
Number of pages9
JournalFuture Oncology
Volume14
Issue number2
DOIs
StatePublished - Jan 2018

Fingerprint

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Bone Marrow
Mutation
Basophils
Manuscripts
Gene Fusion
Leukocytosis
Hematopoietic Stem Cells
PubMed
Cytogenetics
Monocytes
Neutrophils
Transplants
Therapeutics

Keywords

  • actionable mutation
  • atypical chronic myeloid leukemia
  • decitabine
  • hematopoietic stem cell transplant
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Atypical chronic myeloid leukemia : A rare entity with management challenges. / Dhakal, Prajwal; Gundabolu, Krishna; Amador, Catalina; Rayamajhi, Supratik; Bhatt, Vijaya R.

In: Future Oncology, Vol. 14, No. 2, 01.2018, p. 177-185.

Research output: Contribution to journalReview article

@article{5a557d3ed83f44af9d59dbcd27ed100e,
title = "Atypical chronic myeloid leukemia: A rare entity with management challenges",
abstract = "The aim of our study was to review the clinicopathologic features and management of atypical chronic myeloid leukemia (aCML). Relevant manuscripts published in English were searched using PubMed. aCML is diagnosed as per WHO 2016 classification in the presence of leukocytosis ≥13 × 109/l with circulating neutrophil precursors ≥10{\%}, monocytes less than 10{\%}, minimal basophils, hypercellular bone marrow with granulocytic proliferation and dysplasia, bone marrow blast less than 20{\%} and absence of BCR/ABL fusion gene. Common cytogenetic features and mutations include trisomy 8, and mutations in SETBP1 and ETNK1. Median survival is 1-2 years. Hematopoietic stem cell transplant may be the only curative option. Ruxolitinib and dasatinib are emerging therapeutic options. Thus, aCML is a rare entity with poor survival. Novel therapies are needed.",
keywords = "actionable mutation, atypical chronic myeloid leukemia, decitabine, hematopoietic stem cell transplant, targeted therapy",
author = "Prajwal Dhakal and Krishna Gundabolu and Catalina Amador and Supratik Rayamajhi and Bhatt, {Vijaya R}",
year = "2018",
month = "1",
doi = "10.2217/fon-2017-0334",
language = "English (US)",
volume = "14",
pages = "177--185",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Atypical chronic myeloid leukemia

T2 - A rare entity with management challenges

AU - Dhakal, Prajwal

AU - Gundabolu, Krishna

AU - Amador, Catalina

AU - Rayamajhi, Supratik

AU - Bhatt, Vijaya R

PY - 2018/1

Y1 - 2018/1

N2 - The aim of our study was to review the clinicopathologic features and management of atypical chronic myeloid leukemia (aCML). Relevant manuscripts published in English were searched using PubMed. aCML is diagnosed as per WHO 2016 classification in the presence of leukocytosis ≥13 × 109/l with circulating neutrophil precursors ≥10%, monocytes less than 10%, minimal basophils, hypercellular bone marrow with granulocytic proliferation and dysplasia, bone marrow blast less than 20% and absence of BCR/ABL fusion gene. Common cytogenetic features and mutations include trisomy 8, and mutations in SETBP1 and ETNK1. Median survival is 1-2 years. Hematopoietic stem cell transplant may be the only curative option. Ruxolitinib and dasatinib are emerging therapeutic options. Thus, aCML is a rare entity with poor survival. Novel therapies are needed.

AB - The aim of our study was to review the clinicopathologic features and management of atypical chronic myeloid leukemia (aCML). Relevant manuscripts published in English were searched using PubMed. aCML is diagnosed as per WHO 2016 classification in the presence of leukocytosis ≥13 × 109/l with circulating neutrophil precursors ≥10%, monocytes less than 10%, minimal basophils, hypercellular bone marrow with granulocytic proliferation and dysplasia, bone marrow blast less than 20% and absence of BCR/ABL fusion gene. Common cytogenetic features and mutations include trisomy 8, and mutations in SETBP1 and ETNK1. Median survival is 1-2 years. Hematopoietic stem cell transplant may be the only curative option. Ruxolitinib and dasatinib are emerging therapeutic options. Thus, aCML is a rare entity with poor survival. Novel therapies are needed.

KW - actionable mutation

KW - atypical chronic myeloid leukemia

KW - decitabine

KW - hematopoietic stem cell transplant

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85039852266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039852266&partnerID=8YFLogxK

U2 - 10.2217/fon-2017-0334

DO - 10.2217/fon-2017-0334

M3 - Review article

C2 - 29226717

AN - SCOPUS:85039852266

VL - 14

SP - 177

EP - 185

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 2

ER -